Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Today we have some exciting news to share with you.## The biotech industry is gaining momentum in 2024, with emerging companies and their investors adapting to industry changes. Biopharma Dive is offering a trendline that explores this new sense of optimism and provides insights into the challenges and opportunities facing these companies. It covers topics such as the impact of biotech layoffs, AI in biotech, and more. This trendline is independently produced by Biopharma Dive's journalists and is made possible with the support of sponsors.## Biogen is facing challenges in obtaining complete information about its Alzheimer's drug, Leqembi, as its development partner Eisai is leading commercial efforts. Biogen CEO Chris Viehbacher mentioned that there are approximately 3,800 registered patients in the US for Leqembi. Two investors from GV discussed the reset of the biotech industry and building their next drug startups. Kalvista Pharmaceuticals announced the success of its late-stage study on a pill for hereditary angioedema. ProfoundBio raised $112 million in funding for its antibody-drug conjugate development. BioAge secured $170 million in funding for its obesity drug.## Health insurer Elevance has reportedly laid off thousands of employees since September. Alabama-based healthcare provider Baptist Health has filed a lawsuit against Humana, alleging underpayment in the Medicare Advantage program. The state of Washington is considering legislation to regulate hospital mergers. The University of Minnesota is planning to reacquire its medical center from Fairview Health Services. A data breach at an Oklahoma health system has potentially exposed personal information from nearly 2.4 million people. The Federal Trade Commission (FTC) has obtained a $195 million judgment against Simple Health for selling "sham" insurance.## Senseonics has gained expanded Medicare coverage for its implantable continuous glucose monitoring device. A study found that the revision rate for robotic knee replacement surgery is no better than traditional surgery. Several medtech companies have announced job cuts. The FDA seems inclined towards approving Abbott's Triclip. A study conducted by Masimo has found that pulse oximeters are accurate in black patients with low pulse strength.## Novo Nordisk's acquisition of Catalent is facing uncertainty due to manufacturing deviations at a Catalent facility. The weight loss market has been generating hype, but recent drug launches have flopped. Vituity offers clinical leadership and support for healthcare organizations. A webinar discusses the benefits of using a digital hub to improve access and outcomes in the healthcare industry.## Kyverna raised $319 million in an IPO, adding to the momentum of biotech companies going public. Gene editing biotech Metagenomi raised nearly $94 million in its IPO. Alys,

Support the Show.